- A +

Gene Therapy Against Blindness

We are a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. To address these therapeutic areas, we leverage our integrated development platform by combining a gene therapy-based approach with our core technology platforms of mitochondrial targeting sequence, or MTS, and optogenetics.

Our management and scientific teams have extensive experience in gene therapy and drug development, particularly in the field of ophthalmology, and have served in leadership roles at several innovative ophthalmology companies.

Our initial focus has been on developing therapies for severe retinal diseases, with the goal of preserving or restoring vision in patients suffering from sight-threatening ophthalmic diseases.

 

2015 Next events

17-20September2015

ESGCT, September 17-20, 2015, Helsinki, Finland

GenSight will participate to this annual meeting that gathers nearly 1,000 participants from 40 countries as scientists, clinicians and industry professionals to share new data, learn from peers, and discover global advances within the Gene and Cell Therapy field. 

29-30September2015

Phacilitate Cell&Gene Therapy Europe, September 29-30, Barcelona, Spain

GenSight will participate and will give an oral presentation on Day1 in  Focus session 2 on "Early Clinical Strategy: How to efficiently navigate european ATMP regulations on a national basis"

 July 23, 2015

GenSight Biologics Closes $36 Million Series B Preferred Stock Financing

Paris, France, July 23rd, 2015 - GenSight Biologics S.A. (Gensight), a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye, and in the future, of the central nervous system, announced that it has completed a Series B preferred stock financing of approximately $36 million.

Other news

06 July 2015

GenSight Biologics Appoints Thomas Gidoin as Chief Financial Officer & Michael Wyzga to Board of Directors

Paris, France, July 6, 2015 – GenSight Biologics S.A. (GenSight), a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye, and in the future, of the central nervous system, announced the appointments of Thomas Gidoin as Chief Financial Officer and Michael Wyzga as Independent Director.

06 January 2015

SIGHT AGAIN : a collaborative R&D project to restore vision to legally blind patients with retinitis pigmentosa at different stages

GenSight Biologics, Pixium Vision and Fondation Voir et Entendre join forces and benefit from a total €18.5 million funding for SIGHT AGAIN as part of the Investment for the Future. This public - private project with an overall budget of € 47 million aims to restore vision to legally blind patients with retinitis pigmentosa at different stages of the disease.

Read all news

Discover our videos